Improving the methods for evaluating the safety of psychotropic medications in children and adolescents

[1]  J. Swanson,et al.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. , 2001, Pediatrics.

[2]  D. Safer,et al.  Pemoline hepatotoxicity and postmarketing surveillance. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  H. Kraemer,et al.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  F. Benes,et al.  Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. , 2000, Cerebral cortex.

[5]  K. Goa,et al.  Lamotrigine. A review of its use in childhood epilepsy. , 2000, Paediatric drugs.

[6]  A. Sadeh,et al.  Instability of sleep patterns in children with attention-deficit/hyperactivity disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  P. S. Jensen.  ARE STIMULANTS OVERPRESCRIBED , 2000 .

[8]  F. Lynch,et al.  Trends in the prescribing of psychotropic medications to preschoolers. , 2000, JAMA.

[9]  A. Herbst,et al.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. 1971. , 1999, American journal of obstetrics and gynecology.

[10]  M. Boyle,et al.  Treatment of attention-deficit/hyperactivity disorder. , 1999, Evidence report/technology assessment.

[11]  I. Choonara,et al.  Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective study , 1999, Acta paediatrica.

[12]  C. Hoven,et al.  Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  C. Stein,et al.  Making medicines safer--the need for an independent drug safety board. , 1998, The New England journal of medicine.

[14]  P. Jensen,et al.  Medication development and testing in children and adolescents. Current problems, future directions. , 1997, Archives of general psychiatry.

[15]  S. Kumra,et al.  Case study: risperidone-induced hepatotoxicity in pediatric patients. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  J. Swanson,et al.  Case study: adverse response to clonidine. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  D. Safer.  Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. , 1997, Journal of child and adolescent psychopharmacology.

[18]  S. Faraone,et al.  Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[19]  R. Barkley,et al.  Methylphenidate effects on children with Attention Deficit Hyperactivity Disorder: Self-report of symptoms, side-effects, and self-esteem , 1996 .

[20]  G. Koren,et al.  Pemoline‐associated fulminant liver failure: Testing the evidence for causation , 1995, Clinical pharmacology and therapeutics.

[21]  P. Jensen,et al.  Developmental perspectives in pediatric psychopharmacology. , 1995, Psychopharmacology bulletin.

[22]  D. Robinson,et al.  Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines , 1994 .

[23]  A. Pakarinen,et al.  Polycystic Ovaries and Hyperandrogenism in Women Taking Valproate for Epilepsy , 1993 .

[24]  N. Ryan,et al.  Another sudden death in a child treated with desipramine. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  W. Pelham.  Pharmacotherapy for Children with Attention-Deficit Hyperactivity Disorder. , 1993 .

[26]  J. Rabkin,et al.  General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. , 1992, Journal of clinical psychopharmacology.

[27]  B. Spilker.  Guide to clinical trials , 1991 .

[28]  R. Barkley,et al.  Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. , 1990, Pediatrics.

[29]  Mark D. Hoover,et al.  Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. , 1990, Pediatrics.

[30]  D. Hirtz,et al.  Phenobarbital for febrile seizures--effects on intelligence and on seizure recurrence. , 1990, The New England journal of medicine.

[31]  J. Levine.  Ascertainment of side effects in psychopharmacologic clinical trials. , 1990, Psychopharmacology series.

[32]  W. Maier,et al.  Methodology of the Evaluation of Psychotropic Drugs , 1990, Psychopharmacology Series.

[33]  F. Dreifuss,et al.  Valproic acid hepatic fatalities , 1987, Neurology.

[34]  J. Levine,et al.  SAFTEE: a technique for the systematic assessment of side effects in clinical trials. , 1986, Psychopharmacology bulletin.

[35]  A. Harcus,et al.  Post-marketing surveillance of drugs. , 1979, British medical journal.

[36]  A. Herbst,et al.  ADENOCARCINOMA OF THE VAGINA , 1971 .